

Pancreatic Cancer Research and HMGB1 Signaling Pathway

Haijun Gong^{*}, Paolo Zuliani^{*}, Anvesh Komuravelli^{*},
James R. Faeder[#], Edmund M. Clarke^{*}

*


Carnegie Mellon

#



University of Pittsburgh

The Hallmarks of Cancer



D. Hanahan and R. A. Weinberg
Cell, Vol. 100, 57–70, January 7, 2000

Outline

1. Introduction

- HMGB1 Protein
- Important Signaling Pathways

2. Model Building


- BioNetGen Model
- Simulation Results

3. Model Checking

- Statistical Model Checking
- Verification of HMGB1 model

4. Conclusions

The Protein HMGB1



- High-Mobility Group Protein 1 (**HMGB1**):
 - DNA-binding protein and regulates gene transcription
 - released from damaged or stressed cells, etc.
- HMGB1 activates RAGE or TLR2/4
 - **RAGE**: Receptor for Advanced Glycation End products.
 - **TLR**: Toll-like receptor
- RAGE/TLR activation can activate **NF κ B** and **RAS** signaling pathways which causes inflammation or tumorigenesis.

HMGB1 and Pancreatic Cancer

(Lotze *et al.*, UPMC)



Experiments with pancreatic cancer cells:

- **Overexpression of HMGB1/RAGE** is associated with diminished apoptosis, and longer cancer cell survival time.
- **Knockout of HMGB1/RAGE** leads to increased apoptosis, and decreased cancer cell survival.


Our Goals

- We use the **BioNetGen** language (<http://bionetgen.org>) to describe the crosstalk of important signaling pathways activated by HMGB1.
 - We focus on the **p53, RAS, NFkB & RB-E2F** signaling pathways.
 - How the expression level of HMGB1 influences the cell's fate.
- We use **statistical model checking** to formally verify behavioral properties expressed in **temporal logic**:
 - Can express quantitative properties of systems
 - Scalable, can deal with large models

P53-RAS-RB Crosstalk Model

- **First** computational model of HMGB1 signal transduction in tumorigenesis.
- Focus on the crosstalk of **p53**, **RAS**, & **RB** signaling pathways.
- More details in the paper “*Analysis and Verification of the HMGB1 Signaling Pathway*” published in *BMC Bioinformatics 11 (Suppl 7) (2010)*

PI3K-p53 pathway




P53 is a **tumor suppressor**, is mutated in more than **50% of cancers**

Functions of P53:

1. **Induces cell cycle arrest:** P21, etc.
2. **DNA repair**
3. **Initiates apoptosis** – Programmed Cell Death: Bax, etc.

- **Negative feedback loop:**
 $PI3K \rightarrow PIP3 \rightarrow AKT \rightarrow MDM2 \rightarrow p53 \rightarrow MDM2$
- **Positive feedback loop:**
 $p53 \rightarrow PTEN \rightarrow PIP3 \rightarrow AKT \rightarrow MDM2 \rightarrow p53$




RAS-ERK pathway

1. Activation of RAS signaling causes cell growth and survival.
2. RAS family has **three members**: HRAS, KRAS, NRAS.
3. **KRAS mutations** are found in more than **90% of pancreatic cancers**

- RAGE → RAS → RAF → MEK → ERK1/2 → TFs → Cyclin D → Cell-cycle progression
- RAS → PI3K → PIP3 → AKT → MDM2 —| Apoptosis


RB-E2F pathway

- Regulates the G1-S phase transition in the cell cycle.
- E2F** is an **oncoprotein**, activates the transcription of Cyclin E, and it is modulated by RB.
 - RB** is a **tumor suppressor**: prevents the replication of damaged DNA.
 - Cyclin D-CDK4 **phosphorylates** RB, leading to the **activation** of **E2F**.
- CyclinD** —| **RB** —| **E2F** → **CyclinE** → S Phase




31 molecular species
59 reactions


Blue: tumor suppressor
Red: oncoprotein/gene



P53-NFkB-RAS-RB Crosstalk Model

- Crosstalk of p53, **NFkB**, RAS, & RB signaling pathways.
- NFkB protein is involved in **inflammation, cell proliferation** and **apoptosis**.
- NFkB is a **transcription factor** for the pro-apoptotic gene p53, for anti-apoptotic genes Bcl-XL and for the cell-cycle regulatory proteins Myc and Cyclin D.
- More details in the paper “***Computational Modeling and Verification of Signaling Pathways in Cancer***” published in *Algebraic and Numeric Biology Proceedings* (2010).






The BioNetGen Language

begin molecule types

A (b, Y~U~P) # A has a component Y which
 # can be labeled as U (unphosphorylated)
 # or P (phosphorylated)

B (a)

end molecule types





begin reaction rules

A (b) + B (a) <-> A (b!1) . B (a!1)

A (Y~U) -> A (Y~P)

end reaction rules

Ordinary Differential Equations and Stochastic simulation



BioNetGen

- Two Events: PIP3 phosphorylates AKT, and AKT dephosphorylates.

begin species

AKT (d~U) 1e5

AKT (d~p) 0

end species

begin reaction_rules

PIP (c~p) + AKT (d~U) → PIP (c~p) + AKT (d~p) k

AKT (d~p) → AKT (d~U) d

end reaction_rules

- The corresponding ODE is:

$$[\text{AKT}(d\sim p)](t)' = k \cdot [\text{PIP}(c\sim p)](t) \cdot [\text{AKT}(d\sim U)](t) - d \cdot [\text{AKT}(d\sim p)](t)$$

begin parameters


k 1.2e-7

d 1.2e-2

end parameters


Simulations (I)

- Baseline simulation of p53, MDM2, Cyclin D/E in response to HMGB1 release: ODE vs stochastic simulation




Simulations (II)

- Baseline simulation of NF κ B, I κ B, IKK and A20 in response to HMGB1 release.




Simulations (III)



- Overexpression of HMGB1 leads to increase of E2F and Cyclin D/E, decrease of p53.


- Overexpression of AKT represses p53 level

Simulations (IV)



Simulations (V)

- **IKK overexpress** in many cancer cells, it promotes NFκB's transcription activity and accelerate cell proliferation.
- Overexpression of NFκB is common in pancreatic cancer.



Bounded Linear Temporal Logic


- **Bounded Linear Temporal Logic (BLTL):** Extension of LTL with **time bounds** on temporal operators.
- **$F^t a$** – “a will be true in the Future *within time t*”
- **$G^t a$** – “a will be Globally true *between time 0 and t*”
- For example: “# of AKTp reach 4,000 within **20 minutes?**” – **$F^{20} (AKTp \geq 4,000)$**
- Let $\sigma = (s_0, t_0), (s_1, t_1), \dots$ be an execution of the model
 - along states s_0, s_1, \dots
 - the system stays in state s_i for time t_i
- **σ^i :** Execution trace starting at state i .

Verification of BioNetGen Models

- Given a stochastic BioNetGen model \mathcal{M} , Temporal property Φ , and a fixed $0 < \theta < 1$, we ask whether $P_{\geq \theta}(\Phi)$ or $P_{< \theta}(\Phi)$.
- For example: “could AKTp reach 4,000 within 20 minutes, with probability at least 0.99?” : $P_{\geq 0.99}(\mathbf{F}^{20}(\text{AKTp} \geq 4,000))$
- Does \mathcal{M} satisfy ϕ with probability at least θ ?
$$\mathcal{M} \models P_{\geq \theta}(\phi)$$
- Draw a sample of system simulations and use Statistical Hypothesis Testing: Null vs. Alternative hypothesis
$$H_0 : \mathcal{M} \models P_{\geq \theta}(\phi) \quad H_1 : \mathcal{M} \models P_{< \theta}(\phi)$$

Statistical Model Checking

Statistical Model Checking of biochemical models: $\mathcal{M} \models P_{\geq\theta}(\Phi)$?



Bayes Factor

- $X = (x_1, \dots, x_n)$ a sample of Bernoulli random variables
- **Prior probabilities** $P(H_0)$, $P(H_1)$ strictly positive, sum to 1
- Ratio of Posterior Probabilities:

$$\boxed{\frac{P(H_0|X)}{P(H_1|X)} = \frac{P(X|H_0)}{P(X|H_1)} \cdot \frac{P(H_0)}{P(H_1)}}$$

Bayes Factor B

- Fix **threshold** $T \geq 1$ and prior probabilities $P(H_0)$, $P(H_1)$.
Continue sampling until
 - Bayes Factor $B > T$: **Accept** H_0
 - Bayes Factor $B < 1/T$: **Reject** H_0

SMC Algorithm

Require: Property $P_{\geq\theta}(\Phi)$, Threshold $T \geq 1$, Prior density g

$n := 0$ {number of traces drawn so far}

$x := 0$ {number of traces satisfying Φ so far}

repeat

$\sigma :=$ draw a sample trace from BioNetGen (iid)

$n := n + 1$

if $\sigma \models \Phi$ **then**

$x := x + 1$

endif

$\mathcal{B} := \text{BayesFactor}(n, x, g)$

until ($\mathcal{B} > T \vee \mathcal{B} < 1/T$)

if ($\mathcal{B} > T$) **then**

return “ H_0 accepted”

else

return “ H_0 rejected”

endif

Verification (I)

- Overexpression of HMGB1 will induce the expression of cell regulatory protein CyclinE.
- We model checked the formula with different initial values of HMGB1, the probability error is 0.001.

$$P_{\geq 0.9} \mathbf{F}^{600} (\text{CyclinE} > 900)$$

HMGB1	# samples	# Success	Result
10^2	9	0	False
10^3	55	16	False
10^6	22	22	True

Verification (II)

- *P53 is expressed at low levels in normal human cells.*
- $P_{\geq 0.9} \mathbf{F}^t (\mathbf{G}^{900} (p53 < 3.3 \times 10^4))$

t(min)	# Samples	# Success	Result	Time (s)
400	53	49	True	597.59
500	23	22	True	271.76
600	22	22	True	263.79

Verification (III)

- Expression level of HMGB1 influence the 1st peak of p53's level.

$$P_{\geq 0.9} \mathbf{F}^{100} (p53 \geq a \ \& \ \mathbf{F}^{100} (p53 \leq 4 \times 10^4))$$

HMGB1	a (x 10 ⁴)	# Samples	# Success	Result	Time (s)
10 ³	5.5	20	3	False	29.02
10 ²	5.5	22	22	True	19.65
10 ²	6.0	45	12	False	56.27
10	6.0	38	37	True	41.50

Verification (IV)

- HMGB1 can activate PI3K, RAS and AKT in large quantities
- Let PI3Kr, RASr, and IKKr be the **fraction** of activated molecules of PI3K, RAS, and IKK, respectively
- We model checked the formula:

$$P_{\geq 0.9} \mathbf{F}^t \mathbf{G}^{180} (\text{PI3Kr} > 0.9 \ \& \ \text{RASr} > 0.8 \ \& \ \text{IKKr} > 0.6)$$

t (min)	# Samples	# Success	Result	Time (s)
90	9	0	False	21.27
110	38	37	True	362.19
120	22	22	True	214.38

Verification (V)

- Coding **oscillations** of NFkB in temporal logic
- Let **R** be the **fraction** of NFkB molecules in the **nucleus**

$P_{\geq 0.9} \mathbf{F}^t (R \geq 0.65 \ \& \ \mathbf{F}^t (R < 0.2 \ \& \ \mathbf{F}^t (R \geq 0.2 \ \& \ \mathbf{F}^t (R < 0.2))))$

HMGB1	t (min)	# Samples	# Success	Result	Time (s)
10^2	45	13	1	False	76.77
10^2	60	22	22	True	111.76
10^2	75	104	98	True	728.65
10^5	30	4	0	False	5.76

Conclusions

- Computational model qualitatively confirmed the previous HMGB1 experimental phenomena.
- Our simulations predict a **dose-dependent** p53, CyclinE, and NFkB response curve to increasing HMGB1 stimulus.
- Statistical Model Checking automatically validate our model with respect to known experimental results.

Future Work

- Parameter estimation
- Combine Machine Learning (Bayesian Network) and Model Checking to infer Gene Regulatory Network
- Multi-cellular systems
- Pancreatic stellate cells

Acknowledgments

- This work supported by the NSF Expeditions in Computing program
- Thanks to Michael T. Lotze (University of Pittsburgh) for calling our attention to HMGB1
- Thanks to Marco E. Bianchi (Università San Raffaele) for discussions on HMGB1

Thank you!

Questions?